Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.61 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.61 |
| ▸ | PPARG | P37231 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1165782 | 0.98 | CYSLTR2 (0.59) | CYSLTR2CYSLTR1PPARGLMNAMEN1 | |
| SCHEMBL28036402 | 0.90 | CYSLTR2 (0.59) | CYSLTR2CYSLTR1PPARGLMNAMEN1 | |
| SCHEMBL28036336 | 0.88 | CYSLTR2 (0.56) | CYSLTR2CYSLTR1PPARGLMNAMEN1 | |
| SCHEMBL21624574 | 0.87 | LMNA (0.61) | CYSLTR2CYSLTR1PPARGLMNAMEN1 | |
| SCHEMBL28158526 | 0.84 | L3MBTL1 (0.56) | MAPTKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL29033404 | 0.81 | PPARG (0.58) | CYSLTR2CYSLTR1PPARGLMNAMEN1 | |
| SCHEMBL11605622 | 0.81 | PPARG (0.60) | CYSLTR2CYSLTR1PPARGLMNAMEN1 | |
| SCHEMBL9214705 | 0.81 | LMNA (0.61) | CYSLTR2CYSLTR1PPARGLMNAMEN1 | |
| SCHEMBL3702040 | 0.80 | PTGS2 (0.47) | LMNAMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL11734054 | 0.79 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1PPARGLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-20260014169-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | AZURITY PHARMACEUTICALS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250281509-A1 | SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSTY | 2025-09-11 | — | — | US | disclosed |
| WO-2025054607-A1 | COMPOSITIONS AND METHODS FOR TREATING SARCOPENIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250032508-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SLAYBACK PHARMA LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-12138271-B2 | Pharmaceutical compositions of testosterone | SLAYBACK PHARMA LLC (US) | 2024-11-12 | — | — | US | disclosed |
| US-20230248742-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SLAYBACK PHARMA LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11642355-B2 | Pharmaceutical compositions of testosterone | SLAYBACK PHARMA LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220202830-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SLAYBACK PHARMA LLC (US) | 2022-06-30 | — | — | US | disclosed |
| US-11311554-B2 | Pharmaceutical compositions of testosterone | SLAYBACK PHARMA LLC (US) | 2022-04-26 | — | — | US | disclosed |
| US-20190307772-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SLAYBACK PHARMA LLC (US) | 2019-10-10 | — | — | US | disclosed |
| EP-2068840-A2 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM | LAB International SRL (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-2049087-A2 | HYDROPHILIC ABUSE DETERRENT DELIVERY SYSTEM | LAB International SRL (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008011595-A9 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM | LAB INTERNAT SRL (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008011595-A2 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM | LAB INTERNATIONAL SRL (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011596-A2 | HYDROPHILIC ABUSE DETERRENT DELIVERY SYSTEM | LAB INTERNATIONAL SRL (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1727520-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005055983-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014169-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SHBG, CYP17A1, AR | CYSLTR2 2512/4885CYSLTR1 2913/4885PPARG 65/4885 |
| US-20230248742-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SHBG, CYP17A1, NR5A1 | CYSLTR2 3310/4885CYSLTR1 3197/4885PPARG 72/4885 |
| US-11311554-B2 | Pharmaceutical compositions of testosterone | SHBG, CYP17A1, NR5A1 | CYSLTR2 2656/4885CYSLTR1 2552/4885PPARG 118/4885 |
| US-12138271-B2 | Pharmaceutical compositions of testosterone | SHBG, CYP17A1, NR5A1 | CYSLTR2 3310/4885CYSLTR1 3197/4885PPARG 72/4885 |
| US-11642355-B2 | Pharmaceutical compositions of testosterone | SHBG, CYP17A1, NR5A1 | CYSLTR2 2835/4885CYSLTR1 2757/4885PPARG 118/4885 |
| US-20190307772-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SHBG, CYP17A1, NR5A1 | CYSLTR2 2656/4885CYSLTR1 2552/4885PPARG 118/4885 |
| US-20220202830-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SHBG, CYP17A1, NR5A1 | CYSLTR2 2835/4885CYSLTR1 2757/4885PPARG 118/4885 |
| US-20250032508-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SHBG, CYP17A1, NR5A1 | CYSLTR2 3310/4885CYSLTR1 3197/4885PPARG 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.